Whoever is expecting deal from the JP Morgan conference will more than likely be very disappointed. I'm thinking there might be a left field clinical trial updates to be released prior to the conference and if not some current or future big holders to decide to buy substantial amount after the conference as they see IMU is undervalue right now like us and somehow there are still some a lot of sellers for them to buy big amount of shares.
BP already know about IMU, they know IMU is tracking well but want more clinical trial data before they make their move like they've always done with other acquisitions.
Ann: Imugene to Present at Annual JPMorgan Healthcare Conference, page-11
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
0.003(5.77%) |
Mkt cap ! $389.5M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.5¢ | 5.2¢ | $326.7K | 6.068M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 392291 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 3216166 | 17 |
View Market Depth
| Last trade - 12.14pm 20/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |